Dr Coupe on the Investigation of IMM60 Plus Pembrolizumab in Advanced Melanoma and NSCLC

Nicholas Coupe, MBBS, PhD, oncologist, Oxford University Hospitals, NHS Foundation Trust, discusses the investigation of IMM60 plus pembrolizumab (Keytruda) in patients with advanced melanoma or metastatic non-small cell lung cancer (NSCLC).

The phase 1/2 IMPORT-201 trial (NCT05709821) is investigating IMM60 monotherapy and in combination with pembrolizumab. Data from the phase 1 portion of the trial presented at the 2023 ASCO Annual Meeting showed that IMM60 was well-tolerated at doses of 1 mg/mg2, 3 mg/mg2, and 9 mg/mg2, although only 12 patients have been treated with the single agent or combination thus far in the first-in-human study, Coupe begins. Only a small number of grade 1/2 toxicities have been reported, and no grade 3 or higher adverse effects have occurred, he says. in patients. Notably, there was not a significant increase in toxicity at increased dose levels, and expansion to additional dose levels is possible, Coupe explains.

Pharmacokinetic data demonstrated that IMM60 reached appropriate concentrations in the blood, he expands. In patients treated with IMM60 alone, tumor reduction has been observed at several sites in a heavily pretreated patient population, Coupe says, noting that there are patients who had exhausted other standard-of-care treatment options.

Moreover, one patient treated with the combination of IMM60 and pembrolizumab experienced a 100% reduction in target lesion in the liver, Coupe continues. This response was observed after 3 months of treatment; however, it is too early to know if that response could be attributed to pembrolizumab or IMM60, and further study and follow-up could help provide additional data regarding the combination, Coupe concludes.